We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+33.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.72B
AUM Growth
-$71.4M
(-2.6%)
Cap. Flow
-$452M
Cap. Flow
% of AUM
-16.6%
Top 10 Holdings %
Top 10 Hldgs %
41.91%
Holding
86
New
16
Increased
22
Reduced
27
Closed
9
Top Buys
| 1 |
SLN
Silence Therapeutics
SLN
|
+$44.1M |
| 2 |
Keros Therapeutics
KROS
|
+$32.8M |
| 3 |
4D Molecular Therapeutics
FDMT
|
+$32.2M |
| 4 |
Cigna
CI
|
+$21.5M |
| 5 |
Immunome
IMNM
|
+$20.5M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$487M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$115M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$67.7M |
| 4 |
Krystal Biotech
KRYS
|
+$31.2M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$25.3M |
Sector Composition
| 1 | Healthcare | 97.54% |
| 2 | Industrials | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Krystal Biotech
KRYS
$10.3B
| $268M | 9.85% |
1,508,250
-224,939
| -13% | -$31.2M |
|
|
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
| $156M | 5.73% |
13,257,286
-1,571,035
| -11% | -$20.1M |
|
|
3
Immunome
IMNM
$2.6B
| $121M | 4.43% |
4,889,554
+1,010,139
| +26% | +$20.5M |
|
4
Scholar Rock
SRRK
$6.48B
| $114M | 4.18% |
6,419,610
+17,105
| +0.3% | +$269K |
|
5
Fate Therapeutics
FATE
$349M
| $96.7M | 3.55% |
13,169,057
| – | – |
|
6
Regenxbio
RGNX
$634M
| $95.9M | 3.52% |
4,551,556
+790,866
| +21% | +$14.1M |
|
|
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $83.3M | 3.06% |
5,296,643
+495,103
| +10% | +$7.62M |
|
8
Kymera Therapeutics
KYMR
$9.39B
| $69.7M | 2.56% |
1,734,089
-89,867
| -5% | -$3.22M |
|
9
ADC Therapeutics
ADCT
$163M
| $68.6M | 2.52% |
15,269,217
-59,100
| -0.4% | -$218K |
|
10
Stoke Therapeutics
STOK
$1.86B
| $68.5M | 2.51% |
5,073,049
+2,447,543
| +93% | +$14.8M |
|
|
AUGX
11
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $67M | 2.46% |
16,380,327
| – | – |
|
12
Nurix Therapeutics
NRIX
$2.48B
| $65.9M | 2.42% |
4,483,016
+1,226,497
| +38% | +$13.2M |
|
13
Biohaven
BHVN
$2.24B
| $63.6M | 2.34% |
1,163,241
-281,124
| -19% | -$13.9M |
|
14
Beam Therapeutics
BEAM
$3.17B
| $62.1M | 2.28% |
1,879,617
+449,834
| +31% | +$14M |
|
15
Zymeworks
ZYME
$1.81B
| $58.5M | 2.15% |
5,560,798
-229,432
| -4% | -$2.55M |
|
16
LivaNova
LIVN
$4.36B
| $58.1M | 2.13% |
1,037,780
-99,288
| -9% | -$5.16M |
|
17
Shattuck Labs
STTK
$647M
| $50.2M | 1.84% |
5,615,489
-4,425
| -0.1% | -$40.5K |
|
18
ALX Oncology
ALXO
$273M
| $48.2M | 1.77% |
4,326,509
+667,245
| +18% | +$9.37M |
|
19
Neurogene
NGNE
$787M
| $47.6M | 1.75% |
935,252
-11,645
| -1% | -$389K |
|
|
AKRO
20
DELISTED
Akero Therapeutics
AKRO
| $47M | 1.72% |
1,858,702
+749,226
| +68% | +$18M |
|
21
Absci
ABSI
$1.65B
| $46.9M | 1.72% |
8,253,316
+222,222
| +3% | +$1M |
|
22
Pliant Therapeutics
PLRX
$69.4M
| $46.1M | 1.69% |
3,097,220
+400,572
| +15% | +$6.61M |
|
|
SLN
23
Silence Therapeutics
SLN
$494M
| $43.8M | 1.61% |
+2,027,669
| New | +$44.1M |
|
24
IDEAYA Biosciences
IDYA
$3.54B
| $40.5M | 1.49% |
922,678
-13,185
| -1% | -$567K |
|
|
25
4D Molecular Therapeutics
FDMT
$611M
| $40.2M | 1.48% |
+1,261,427
| New | +$32.2M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO